In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDER guidance agenda

This article was originally published in The Rose Sheet

Executive Summary

"Minimum Data Elements to be Included in a Serious Adverse Event Report for Monograph OTC Products" is one of 40 guidances the Center for Drug Evaluation and Research plans to develop during 2007. According to the March 19 release, the agenda items are "under development as of the date of this posting." Sunscreens, antiperspirants and treatments for dandruff and acne are among products regulated under FDA over-the-counter monographs. The "Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006" (S 3546), signed into law in late 2006 and effective in December, establishes mandatory reporting of serious adverse events associated with such products (1"The Rose Sheet" Jan. 29, 2007, p. 7). The list of guidances includes "Labeling of Over-the-Counter Skin Protectant Drug Products"...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014618

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel